Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh.

"Declarations Ethics approval and consent to participateThe institutional review board (IRB) of the International Centre for Diarrhoeal Disease Research, Bangladesh (https://www.icddrb.org/) reviewed and approved the study protocol (PR-23014). The Institutional Review Board at the Centers for Disease Control and Prevention (Atlanta, GA, USA) relied on the International Centre for Diarrhoeal Disease Research, Bangladesh (https://www.icddrb.org/) approval. We will obtain written informed consent from all study participants. The study team will provide detailed oral and written information in the local language (Bangla) on research aims, objectives, risks and benefits of participation, maintaining confidentiality, the right not to participate and/or withdraw conflicts of interest, and compensation. After being reminded that their participation is entirely voluntary and that any information they provide will be kept strictly confidential, participants will be asked to sign the consent form. Consent for publicationNot Applicable. DisclaimerThe findings and conclusions in this report are those of the authors and do not necessarily represent the US Centers for Disease Control and Prevention official position. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The study was funded by the US Centers for Disease Control and Prevention (CDC), Atlanta (https://www.cdc.gov/). The Grant No is GR-01846 (cooperative agreement number U01GH002259). The funder had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results."

"Trial registration The Clinicaltrials.gov registration number is NCT05996549. The registration for the protocol version 2.0 took place in August 2023, with the initial participant being enrolled in March 2022."